主题：睡前消息422文稿：马督工悬赏5万，保卫连花清瘟 -- 万年看客

马逆的节目我现在不看了，他这种这么长篇大论的又是股票，又是上海采购啥的，牵扯很多地方。但以我没精细的阅读来看，马逆这一堆东西杂七杂八虽然多，根子里的味道还是那一套。就引文里，本质意思就是中医无效，利用who炒作，上海政法发莲花是有py交易嫌疑，而骂马逆的人是资本的看门狗，而马逆是揭发py交易，为人民谋福利的正义白莲花自媒体。这是我大致看了看的中心思想总结，你如果有不同意见，可以把你对引文的中心思想总结告诉我。

马逆这一套就是连环搅浑水话术，他是在说中医疗效？利用who证券交易欺诈？还是政府py交易？都不是。马逆这是给他的主子们对冲WHO对中医正面肯定的影响。

我没兴趣看马逆说东说西，东拉西扯。他这么说，显然是因为有强烈支持中医的东西，让后台老板们觉得需要对冲影响了。我们看看WHO说了些什么，会引发这种民科级别的媒体操作的反中医对冲操作。

WHO Expert Meeting on Evaluation of Traditional Chinese Medicine in the Treatment of COVID-19

一看这个我就明白了，马逆为什么需要跳出来了。

这是WHO的官方正式会议报告，17页，不是很长，可以下下来看看。 这个标题就说明一切问题了， 中医治疗新冠的作用评估。

WHO Expert Meeting on Evaluation of

Traditional Chinese Medicine

in the Treatment of COVID-19

(28 February – 2 March 2022)

Background

Following a high-level policy dialogue between the Director-General of WHO and China’s National Administration of Traditional Chinese Medicine (NATCM) in Geneva on 17 January 2022, WHO decided to convene a meeting of experts to evaluate the role of Traditional Chinese Medicine (TCM) in the treatment of COVID-19. The subsequent Expert Meeting on Evaluation of Traditional Chinese Medicine in the Treatment of COVID-19 was held virtually

from 28 February to 02 March 2022 from 13:00 to 16:00 Central European Time each day.

The 21 international experts from the six WHO regions included five members of the WHO

Expert Advisory Panel, representatives of eight WHO collaborating centres, three members

of the WHO International Regulatory Cooperation for Herbal Medicines (IRCH), and members of the China Academy of Chinese Medical Sciences. Technical staff from WHO headquarters,regional and country offices also attended the meeting.

The meeting considered three reports on traditional Chinese medicine and COVID-19 –

including on clinical service, research and evidence-based evaluation provided by national

expert groups in China. The evidence-based evaluation report focused on outcomes from the

reports as well from 12 randomized controlled trials (RCTs) which had been registered and

published. The objectives of the meeting were:

背景介绍，咋不是WHO砖家，但The 21 international experts from the six WHO regions included five members of the WHO Expert Advisory Panel, representatives of eight WHO collaborating centres, three members

of the WHO International Regulatory Cooperation for Herbal Medicines (IRCH),

总之这个阵容貌似不低，规格好像很高的样子 21 个国际专家，6大区域， 5个WHO顾问团专家， 3位WHO草药专家。

Key findings of the Expert Meeting •

The experts agreed that the evidence evaluation reports applied appropriate and

rigorous methodology to determine the current level of clinical evidence and safety of

the studied TCM interventions used in the trials.

• The experts acknowledged that the included trials involved heterogeneous settings

and various types of patients and outcome measures.

• In addition to routine treatment, the results from the studied TCMs suggest that, on

the basis of clinically relevant outcome measures, the studied TCMs are beneficial in

the treatment of COVID-19, particularly in mild-to-moderate cases.

• There are promising data to suggest that TCM is beneficial in reducing the risk of

progression from mild-to-moderate cases to severe COVID-19.

• The evidence on the benefit of TCM injection for severe cases is limited, and further

evaluation is critically needed.

• For mild-to-moderate cases, there is encouraging evidence that the studied TCMs,

when administered as add-on interventions to conventional treatment, may shorten

the time for viral clearance, resolution of clinical symptoms and length of hospital stay

when compared to conventional treatment alone. • The results of the TCM trials do not substantiate the use of any specific plant species

outside the general TCM framework in the context of COVID-19. • The studied TCM interventions given in addition to conventional treatment were well

tolerated and have a safety profile that is comparable to that of conventional

treatment alone.

• There is encouraging evidence that early application of TCM may result in better

clinical outcomes for patients with mild-to-moderate COVID-19. • Despite inherent limitations, the results from the selected RCTs justify further

investments in clinical trials to evaluate the potential benefits of selected TCMs in the

management of COVID-19.

这里英文也不是很复杂，写的也非常清楚了，

the studied TCMs are beneficial in the treatment of COVID-19, particularly in mild-to-moderate cases.

中医对治疗新冠有效，尤其对轻症和中等症状。

There are promising data to suggest that TCM is beneficial in reducing the risk of

progression from mild-to-moderate cases to severe COVID-19.

数据表明中医能减少新冠重症

Recommendations to WHO

The Expert Meeting recommended to WHO:

• to share the outcomes of this consultation with Member States in a timely manner

given the evolving nature of COVID-19 globally; • to encourage Member States to consider the integration of traditional medicine

interventions such as TCM in planning for the clinical management of COVID-19 in the

context of their health-care systems and regulatory frameworks; • to provide technical support to Member States for the application of TCM in practice

and in further research; • to facilitate international clinical trials to further evaluate the potential benefits and

safety of TCM for treatment of persons with COVID-19 across the care continuum; • to encourage Member States to consider the integrative care model that has been

developed and applied in China.

WHO的建议

这里基本就是鼓励各个成员国使用中医(TCM)来治疗新冠。

可以说，WHO的这个专家会议的ppt写的非常清楚，结论也给的很明白。中医是有用的，鼓励和建议各个成员国使用中医中药来治疗新冠。

什么是正题？这才是正题。马逆那些东拉西扯算个屁正题。是的，WHO这个高级别专家会议里是好像没有专门提连花清瘟（我没仔细看，毕竟17页英文）。但WHO这个高级别专家会议也非常明确的肯定了中医中药的效果并且正式对所有会员国给出了推广建议。

恰恰在WHO的高级别专家会议做出了相当明确的对中医中药治疗新冠有效性肯定，并且建议所有会员国推广中医中药治疗新冠的时候。马逆跳出来在这里东拉西扯，他说的东西里，有多少真的？

这应该是马逆自己的话吧

这是WHO 报告

Recommendations to WHO

The Expert Meeting recommended to WHO:

Recommendations to Member States

The Expert Meeting recommended to Member States:

这是专家会议的结论，可不是说中国自己人自说自话就算了的。

人家WHO专家会议里的结论和马逆说的，有TMD一个词是对的上的吗？

我看之前还觉得马逆这种玩意可能只是蠢，看了WHO的报告后，马逆这个玩意他绝对是坏。还TMD的 “学英语真的很重要，不学就会被人关到信息笼子里驯化。”

我呸。